代谢组学特征可预测HIV/HCV合并感染者的肝病事件
在126例HIV/HCV合并感染者中开展巢式病例对照研究,利用多种定量代谢组学检测建立预测终末期肝病(ESLD)事件的预后模型。基线模型AUC为0.79,联合代谢物模型AUC达0.84-0.89,可提前2年识别高风险患者。
要点
- 代谢组学模型可提前2年预测HIV/HCV患者ESLD事件。
- 联合代谢物模型AUC为0.84-0.89,灵敏度0.70,特异度0.85。
- 代谢物定量可能辅助早期识别高危患者。
核心结论
- 定量检测一组新型代谢物可能有助于更早识别HIV/HCV合并感染者中ESLD临床事件风险最高者。
研究设计与样本
- 在126例HIV/HCV合并感染者中开展巢式病例对照研究,使用多种定量代谢组学检测建立预测ESLD事件的预后模型。
主要发现
- 包含人口学和临床数据的基线模型AUC为0.79。
- 基线联合氨基酸、脂质代谢物或全部代谢物的三个模型AUC为0.84-0.89,可提前2年区分ESLD并发症风险。
- 全部代谢物联合模型灵敏度0.70,特异度0.85,阳性似然比4.78,阴性似然比0.35。
关键数值与推荐
- ESLD事件包括腹水、肝性脑病、肝细胞癌、食管静脉曲张出血和自发性细菌性腹膜炎。
- 基线模型AUC为0.79;联合代谢物模型AUC为0.84-0.89。
- 全部代谢物联合模型灵敏度0.70,特异度0.85,阳性似然比4.78,阴性似然比0.35。
临床怎么用
- 对于HIV/HCV合并感染者,可考虑代谢组学检测辅助早期风险分层,识别需加强监测或干预的高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advanced liver disease due to hepatitis C virus (HCV) is a leading cause of human immunodeficiency virus (HIV)-related morbidity and mortality. There remains a need to develop noninvasive predictors of clinical outcomes in persons with HIV/HCV coinfection. METHODS: We conducted a nested case-control study in 126 patients with HIV/HCV and utilized multiple quantitative metabolomic assays to identify a prognostic profile that predicts end-stage liver disease (ESLD) events including ascites, hepatic encephalopathy, hepatocellular carcinoma, esophageal variceal bleed, and spontaneous bacterial peritonitis. Each analyte class was included in predictive modeling, and area under the receiver operator characteristic curves (AUC) and accuracy were determined. RESULTS: The baseline model including demographic and clinical data had an AUC of 0.79. Three models (baseline plus amino acids, lipid metabolites, or all combined metabolites) had very good accuracy (AUC, 0.84-0.89) in differentiating patients at risk of developing an ESLD complication up to 2 years in advance. The all combined metabolites model had sensitivity 0.70, specificity 0.85, positive likelihood ratio 4.78, and negative likelihood ratio 0.35. CONCLUSIONS: We report that quantification of a novel set of metabolites may allow earlier identification of patients with HIV/HCV who have the greatest risk of developing ESLD clinical events.
引用
- Naggie S, Lusk S, Thompson JW, et al. Metabolomic Signature as a Predictor of Liver Disease Events in Patients With HIV/HCV Coinfection. J Infect Dis. 2020. PMID: 32502252. doi:10.1093/infdis/jiaa316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。